Breast Cancer, HIV Drugs May Face Tougher Part D Climate Under Protected Class Proposal
Executive Summary
Medicare proposed rule exposes Part D protected class drugs to threat of formulary exclusion if price increases exceed a certain threshold. Here's how it might play out for cancer and HIV drugs.
You may also be interested in...
Part D Protected Class Management Tools To Save Medicare $1.85bn
CMS proposed rule would not eliminate any protected classes but would allow plans to impose additional restrictions on drugs in those classes. Proposal also codifies step therapy for Part B drugs.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.